Rafał Szarek
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Rafał Szarek has a total of 34 co-authors. Here are the top co-authors by number of shared publications:
- Agnieszka Kafara
Jagiellonian University Medical College, Krakow, Poland
10 shared publications - Dominika Jurczak
Faculty of Medical Sciences in Zabrze, Medical University of Silesia, Katowice, Poland
10 shared publications - Donata Kowalczyk
5th Military Hospital with Polyclinic in Cracow, Krakow, Poland
10 shared publications - Julia Koronczok-Matusiak
J. Gromkowski Voivodship Specialist Hospital in Wrocław, Wrocław, Poland
10 shared publications - Katarzyna Michta
Medical University of Gdansk, Gdansk, Poland
10 shared publications - Konrad Kulka
Municipal Hospital in Zabrze, Zabrze, Poland
10 shared publications
Latest Publications
- Open Access
- 16 November 2026
- Published by Uniwersytet Mikolaja Kopernika/Nicolaus Copernicus University in Journal of Education, Health and Sport
- Vol. 95
Probiotics in neurodegenerative disorders
Background:Neurodegenerative disorders, including Alzheimer's disease (AD), Parkinson's disease (PD), multiple sclerosis (MS), and amyotrophic lateral sclerosis (ALS), are associated with chronic neuroinflammation and gut microbiota dysbiosis. Increasing evidence suggests that modulation of the microbiota–gut–brain axis with probiotics may represent a novel therapeutic strategy. Aim:To summarize current evidence on the effects of probiotic supplementation in AD, PD, MS, and ALS, focusing on potential mechanisms of action and therapeutic outcomes. Material and methods: A review of scientific literature concerning the influence of gut microbiota on the nervous system through the microbiota-gut-brain axis was conducted. Clinical and preclinical studies evaluating the effectiveness of probiotic therapy in selected neurodegenerative diseases were analyzed. Results: Probiotic supplementation demonstrated beneficial effects across several neurodegenerative disorders. In AD, probiotics improved cognitive performance, reduced inflammatory markers, and attenuated oxidative stress. In PD, they alleviated gastrointestinal symptoms, improved bowel function, enhanced motor performance, and reduced systemic inflammation. In MS, probiotics decreased pro-inflammatory cytokine expression, promoted anti-inflammatory immune responses, and increased brain-derived neurotrophic factor levels. Experimental ALS studies indicated restoration of gut microbiota, improved intestinal barrier integrity, delayed disease progression, and prolonged survival in animal models. Conclusion: Probiotics demonstrate promising therapeutic potential in treating neurodegenerative diseases through modulation of gut microbiota and influence on the gut-brain axis. However, further clinical studies are necessary to confirm their clinical significance and biological effects.
- 16 November 2026
- Published by Uniwersytet Mikolaja Kopernika/Nicolaus Copernicus University in Journal of Education, Health and Sport
- Vol. 95
Open AccessProbiotics in neurodegenerative disorders
Background:Neurodegenerative disorders, including Alzheimer's disease (AD), Parkinson's disease (PD), multiple sclerosis (MS), and amyotrophic lateral sclerosis (ALS), are associated with chronic neuroinflammation and gut microbiota dysbiosis. Increasing evidence suggests that modulation of the microbiota–gut–brain axis with probiotics may represent a novel therapeutic strategy. Aim:To summarize current evidence on the effects of probiotic supplementation in AD, PD, MS, and ALS, focusing on potential mechanisms of action and therapeutic outcomes. Material and methods: A review of scientific literature concerning the influence of gut microbiota on the nervous system through the microbiota-gut-brain axis was conducted. Clinical and preclinical studies evaluating the effectiveness of probiotic therapy in selected neurodegenerative diseases were analyzed. Results: Probiotic supplementation demonstrated beneficial effects across several neurodegenerative disorders. In AD, probiotics improved cognitive performance, reduced inflammatory markers, and attenuated oxidative stress. In PD, they alleviated gastrointestinal symptoms, improved bowel function, enhanced motor performance, and reduced systemic inflammation. In MS, probiotics decreased pro-inflammatory cytokine expression, promoted anti-inflammatory immune responses, and increased brain-derived neurotrophic factor levels. Experimental ALS studies indicated restoration of gut microbiota, improved intestinal barrier integrity, delayed disease progression, and prolonged survival in animal models. Conclusion: Probiotics demonstrate promising therapeutic potential in treating neurodegenerative diseases through modulation of gut microbiota and influence on the gut-brain axis. However, further clinical studies are necessary to confirm their clinical significance and biological effects.
- Open Access
- 25 September 2026
- Published by RS Global Sp. z O.O. in International Journal of Innovative Technologies in Social Science
- Vol. 5 (3(51))
THE IMPACT OF STRESS ON THE DEVELOPMENT OF CARDIOVASCULAR DISEASES
Background: Cardiovascular disease (CVD) remains the leading cause of death worldwide despite advances in the identification and treatment of classic risk factors. Accumulating evidence suggests that psychosocial stress may play a significant role in the development and progression of CVD through biological and behavioral mechanisms. Objective: The aim of the study was to summarize the current knowledge on the relationship between psychosocial stress and cardiovascular diseases, with particular emphasis on the pathophysiological mechanisms underlying this relationship and the possibilities of stress reduction in the prevention and treatment of CVD. Methods: A narrative literature review was conducted using PubMed, Nature Reviews, and Google Scholar. Scientific publications published primarily between 2014 and 2025 were analyzed, including systematic reviews, meta-analyses, cohort studies, clinical trials, experimental studies, and epidemiological reports. Papers on the biological and psychological mechanisms linking psychosocial stress with cardiovascular diseases and interventions aimed at reducing stress were included. Results: Psychosocial stress should be viewed as a multidimensional risk factor for cardiovascular disease, potentially contributing to both its development and progression. Incorporating stress assessment and implementing effective stress reduction strategies may be a valuable complement to current CVD prevention and treatment strategies. Further research involving large patient populations is needed to determine the role of stress-reducing interventions in routine cardiac care.
- 25 September 2026
- Published by RS Global Sp. z O.O. in International Journal of Innovative Technologies in Social Science
- Vol. 5 (3(51))
Open AccessTHE IMPACT OF STRESS ON THE DEVELOPMENT OF CARDIOVASCULAR DISEASES
Background: Cardiovascular disease (CVD) remains the leading cause of death worldwide despite advances in the identification and treatment of classic risk factors. Accumulating evidence suggests that psychosocial stress may play a significant role in the development and progression of CVD through biological and behavioral mechanisms. Objective: The aim of the study was to summarize the current knowledge on the relationship between psychosocial stress and cardiovascular diseases, with particular emphasis on the pathophysiological mechanisms underlying this relationship and the possibilities of stress reduction in the prevention and treatment of CVD. Methods: A narrative literature review was conducted using PubMed, Nature Reviews, and Google Scholar. Scientific publications published primarily between 2014 and 2025 were analyzed, including systematic reviews, meta-analyses, cohort studies, clinical trials, experimental studies, and epidemiological reports. Papers on the biological and psychological mechanisms linking psychosocial stress with cardiovascular diseases and interventions aimed at reducing stress were included. Results: Psychosocial stress should be viewed as a multidimensional risk factor for cardiovascular disease, potentially contributing to both its development and progression. Incorporating stress assessment and implementing effective stress reduction strategies may be a valuable complement to current CVD prevention and treatment strategies. Further research involving large patient populations is needed to determine the role of stress-reducing interventions in routine cardiac care.
- Open Access
- 18 September 2026
- Published by RS Global Sp. z O.O. in International Journal of Innovative Technologies in Social Science
- Vol. 5 (3(51))
THE GUT-BRAIN AXIS: EXPLORING THE IMPACT OF GUT MICROBIOTA ON MENTAL HEALTH
The microbiota-gut-brain axis represents a complex bidirectional communication network linking the intestinal microbiota with the central nervous system through neural, endocrine, immune, and metabolic pathways. Growing evidence suggests that alterations in gut microbiota composition may contribute to the pathophysiology of several mental disorders, including depression, anxiety disorders, bipolar disorder, and attention-deficit/hyperactivity disorder. This review aims to summarize current knowledge on the mechanisms by which gut microbiota may influence mental health and to discuss microbiota-targeted therapeutic approaches. Dysbiosis may affect brain function through vagus nerve signaling, hypothalamic-pituitary-adrenal axis activation, increased intestinal permeability, systemic inflammation, cytokine release, altered neurotransmitter metabolism, and reduced production of short-chain fatty acids. Studies indicate that individuals with psychiatric disorders often show reduced microbial diversity, depletion of beneficial anti-inflammatory and butyrate-producing bacteria, and enrichment of pro-inflammatory microbial taxa. These changes may promote neuroinflammation, oxidative stress, impaired stress regulation, and disturbances in serotonin, dopamine, gamma-aminobutyric acid, and tryptophan-related pathways. The review also examines the potential role of probiotics, prebiotics, synbiotics and fecal microbiota transplantation in modulating the gut microbiome and improving psychiatric symptoms. Although some clinical and experimental findings suggest beneficial effects, especially in depression and anxiety, the available evidence remains heterogeneous. Further well-designed, long-term clinical studies, are recquired to clarify causal mechanisms, identify effective microbial interventions, and determine their place in mental health prevention and treatment.
- 18 September 2026
- Published by RS Global Sp. z O.O. in International Journal of Innovative Technologies in Social Science
- Vol. 5 (3(51))
Open AccessTHE GUT-BRAIN AXIS: EXPLORING THE IMPACT OF GUT MICROBIOTA ON MENTAL HEALTH
The microbiota-gut-brain axis represents a complex bidirectional communication network linking the intestinal microbiota with the central nervous system through neural, endocrine, immune, and metabolic pathways. Growing evidence suggests that alterations in gut microbiota composition may contribute to the pathophysiology of several mental disorders, including depression, anxiety disorders, bipolar disorder, and attention-deficit/hyperactivity disorder. This review aims to summarize current knowledge on the mechanisms by which gut microbiota may influence mental health and to discuss microbiota-targeted therapeutic approaches. Dysbiosis may affect brain function through vagus nerve signaling, hypothalamic-pituitary-adrenal axis activation, increased intestinal permeability, systemic inflammation, cytokine release, altered neurotransmitter metabolism, and reduced production of short-chain fatty acids. Studies indicate that individuals with psychiatric disorders often show reduced microbial diversity, depletion of beneficial anti-inflammatory and butyrate-producing bacteria, and enrichment of pro-inflammatory microbial taxa. These changes may promote neuroinflammation, oxidative stress, impaired stress regulation, and disturbances in serotonin, dopamine, gamma-aminobutyric acid, and tryptophan-related pathways. The review also examines the potential role of probiotics, prebiotics, synbiotics and fecal microbiota transplantation in modulating the gut microbiome and improving psychiatric symptoms. Although some clinical and experimental findings suggest beneficial effects, especially in depression and anxiety, the available evidence remains heterogeneous. Further well-designed, long-term clinical studies, are recquired to clarify causal mechanisms, identify effective microbial interventions, and determine their place in mental health prevention and treatment.
- Open Access
- 15 September 2026
- Published by Uniwersytet Mikolaja Kopernika/Nicolaus Copernicus University in Quality in Sport
- Vol. 72, 74847
Urinary Incontinence in Female Athletes: Prevalence, Mechanisms, Risk Factors and Management. A Narrative Review
Background. While urinary incontinence (UI) frequently affects active women, it is markedly more prevalent among competitive athletes. Repeated impacts and heavy external loads elevate intra-abdominal pressure beyond the counter-force capacity of the pelvic floor. The condition remains systematically under-reported.Aim. To synthesise evidence (2019–2026) on prevalence, mechanisms, risk factors, and management of UI in competitive female athletes.Material and methods. A narrative review of observational studies and intervention trials in athletic populations indexed in PubMed, Scopus, Web of Science, and SPORTDiscus. Data were synthesised thematically.Results. Prevalence ranged from ~26% to >80%, varying by case definition. Leakage clustered during tasks generating steep pressure transients: landings, jumps, tackles, and heavy lifts. Age and parity were the most frequent correlates, though not in every cohort; years of training were not. Cumulative loading, rather than acute fatigue, was associated with symptom onset. Pelvic floor muscle training (PFMT) reduced leakage without requiring gains in maximal strength, whereas a coach-delivered programme lacking professional guidance did not.Conclusions. Athletic UI is highly prevalent, under-reported, yet modifiable. Routine screening and professionally guided PFMT are warranted.
- 15 September 2026
- Published by Uniwersytet Mikolaja Kopernika/Nicolaus Copernicus University in Quality in Sport
- Vol. 72, 74847
Open AccessUrinary Incontinence in Female Athletes: Prevalence, Mechanisms, Risk Factors and Management. A Narrative Review
Background. While urinary incontinence (UI) frequently affects active women, it is markedly more prevalent among competitive athletes. Repeated impacts and heavy external loads elevate intra-abdominal pressure beyond the counter-force capacity of the pelvic floor. The condition remains systematically under-reported.Aim. To synthesise evidence (2019–2026) on prevalence, mechanisms, risk factors, and management of UI in competitive female athletes.Material and methods. A narrative review of observational studies and intervention trials in athletic populations indexed in PubMed, Scopus, Web of Science, and SPORTDiscus. Data were synthesised thematically.Results. Prevalence ranged from ~26% to >80%, varying by case definition. Leakage clustered during tasks generating steep pressure transients: landings, jumps, tackles, and heavy lifts. Age and parity were the most frequent correlates, though not in every cohort; years of training were not. Cumulative loading, rather than acute fatigue, was associated with symptom onset. Pelvic floor muscle training (PFMT) reduced leakage without requiring gains in maximal strength, whereas a coach-delivered programme lacking professional guidance did not.Conclusions. Athletic UI is highly prevalent, under-reported, yet modifiable. Routine screening and professionally guided PFMT are warranted.
- Open Access
- 14 September 2026
- Published by Uniwersytet Mikolaja Kopernika/Nicolaus Copernicus University in Quality in Sport
- Vol. 72, 74881
Sports-Related Ocular Injuries: Incidence, Prevention and Awareness Among Athletes: A Narrative Review
Background. Eye trauma in sport is common, often severe, and in most cases preventable. It continues to affect athletes from recreational play through professional competition, and although protective eyewear prevents the majority of these injuries, its use is inconsistent from one sport and athlete group to the next. Aim. This review synthesizes current evidence on the incidence, mechanisms, and prevention of sports-related ocular injuries, focusing on how effective protective eyewear is and how consistently athletes actually wear it. Material and methods. PubMed was searched for studies on sports-related ocular injuries, their prevention, and eyewear use among athletes. Thirty sources published between 2017 and 2026 met the inclusion criteria and were grouped by theme. Results. Racquet sports, ball sports, combat sports, and ice hockey accounted for most reported ocular injuries. Eyewear meeting recognized safety standards cut both the frequency and severity of injury substantially, while prescription glasses, contact lenses, and lensless guards gave comparatively little protection. Mandates requiring eyewear were linked to marked drops in injury rates, and the biggest gains came from combining mandates with education. Awareness of eye-injury risk remained low even so, especially among younger and amateur athletes, and eyewear use showed the same pattern. Conclusions. The case for protective eyewear as a means of preventing sports-related ocular injury is strong, but awareness and adoption still lag behind it at most levels of competition. Pairing athlete and coach education with enforceable eyewear policy looks like the most promising route to reducing preventable vision loss in sport.
- 14 September 2026
- Published by Uniwersytet Mikolaja Kopernika/Nicolaus Copernicus University in Quality in Sport
- Vol. 72, 74881
Open AccessSports-Related Ocular Injuries: Incidence, Prevention and Awareness Among Athletes: A Narrative Review
Background. Eye trauma in sport is common, often severe, and in most cases preventable. It continues to affect athletes from recreational play through professional competition, and although protective eyewear prevents the majority of these injuries, its use is inconsistent from one sport and athlete group to the next. Aim. This review synthesizes current evidence on the incidence, mechanisms, and prevention of sports-related ocular injuries, focusing on how effective protective eyewear is and how consistently athletes actually wear it. Material and methods. PubMed was searched for studies on sports-related ocular injuries, their prevention, and eyewear use among athletes. Thirty sources published between 2017 and 2026 met the inclusion criteria and were grouped by theme. Results. Racquet sports, ball sports, combat sports, and ice hockey accounted for most reported ocular injuries. Eyewear meeting recognized safety standards cut both the frequency and severity of injury substantially, while prescription glasses, contact lenses, and lensless guards gave comparatively little protection. Mandates requiring eyewear were linked to marked drops in injury rates, and the biggest gains came from combining mandates with education. Awareness of eye-injury risk remained low even so, especially among younger and amateur athletes, and eyewear use showed the same pattern. Conclusions. The case for protective eyewear as a means of preventing sports-related ocular injury is strong, but awareness and adoption still lag behind it at most levels of competition. Pairing athlete and coach education with enforceable eyewear policy looks like the most promising route to reducing preventable vision loss in sport.
- Open Access
- 25 August 2026
- Published by RS Global Sp. z O.O. in International Journal of Innovative Technologies in Social Science
- Vol. 2 (3(51))
NATALIZUMAB IN MULTIPLE SCLEROSIS – A REVIEW OF DIFFERENT DOSING REGIMENS, SIDE EFFECTS, COMPARISON WITH OTHER DISEASE-MODIFYING THERAPIES WITH ADDITIONAL ATTENTION TO USE IN PREGNANCY AND THE PEDIATRIC POPULATION
Objective: The aim of this review was to evaluate the clinical efficacy, optimization of dosing regimens, safety profile, and socioeconomic aspects of natalizumab (NTZ) use in the treatment of multiple sclerosis (MS), with a additional focus on pregnant and pediatric populations. Methodology: A systematic review of the PubMed database was conducted, identifying 220 records. Thirty-two publications meeting the criteria regarding the mechanism of action, efficacy, adverse event profile, and comparison with other disease-modifying therapies (DMTs) were included in the final analysis. Results: The analysis demonstrated that the extended interval dosing (EID, every 6 weeks) regimen maintains clinical and radiological efficacy comparable to the standard interval dosing (SID, every 4 weeks), while significantly reducing the risk of progressive multifocal leukoencephalopathy (PML) by 88–94%. It was recognized that natalizumab is safer than other DMTs, such as ocrelizumab, without compromising efficacy. In the pediatric population, NTZ showed the highest efficacy in reducing relapse rates compared to fingolimod and injectable therapies. In pregnant women, continuing treatment until the 34th week prevents postpartum rebound relapses and improves EDSS scores, showing no teratogenic effects. Economically, the subcutaneous form of NTZ and the use of EID generate significant direct and societal cost savings. Conclusions: Natalizumab remains a highly effective and cost-efficient therapeutic option for the treatment of relapsing-remitting MS. Personalization of treatment through the EID regimen and the subcutaneous formulation allows for an improved safety profile and patient quality of life, while simultaneously reducing the systemic burden on healthcare.
- 25 August 2026
- Published by RS Global Sp. z O.O. in International Journal of Innovative Technologies in Social Science
- Vol. 2 (3(51))
Open AccessNATALIZUMAB IN MULTIPLE SCLEROSIS – A REVIEW OF DIFFERENT DOSING REGIMENS, SIDE EFFECTS, COMPARISON WITH OTHER DISEASE-MODIFYING THERAPIES WITH ADDITIONAL ATTENTION TO USE IN PREGNANCY AND THE PEDIATRIC POPULATION
Objective: The aim of this review was to evaluate the clinical efficacy, optimization of dosing regimens, safety profile, and socioeconomic aspects of natalizumab (NTZ) use in the treatment of multiple sclerosis (MS), with a additional focus on pregnant and pediatric populations. Methodology: A systematic review of the PubMed database was conducted, identifying 220 records. Thirty-two publications meeting the criteria regarding the mechanism of action, efficacy, adverse event profile, and comparison with other disease-modifying therapies (DMTs) were included in the final analysis. Results: The analysis demonstrated that the extended interval dosing (EID, every 6 weeks) regimen maintains clinical and radiological efficacy comparable to the standard interval dosing (SID, every 4 weeks), while significantly reducing the risk of progressive multifocal leukoencephalopathy (PML) by 88–94%. It was recognized that natalizumab is safer than other DMTs, such as ocrelizumab, without compromising efficacy. In the pediatric population, NTZ showed the highest efficacy in reducing relapse rates compared to fingolimod and injectable therapies. In pregnant women, continuing treatment until the 34th week prevents postpartum rebound relapses and improves EDSS scores, showing no teratogenic effects. Economically, the subcutaneous form of NTZ and the use of EID generate significant direct and societal cost savings. Conclusions: Natalizumab remains a highly effective and cost-efficient therapeutic option for the treatment of relapsing-remitting MS. Personalization of treatment through the EID regimen and the subcutaneous formulation allows for an improved safety profile and patient quality of life, while simultaneously reducing the systemic burden on healthcare.
- Open Access
- 8 August 2026
- Published by Uniwersytet Mikolaja Kopernika/Nicolaus Copernicus University in Quality in Sport
- Vol. 67, 74323
Comparison of different exercise modalities in women with polyendocrine metabolic ovarian syndrome: a narrative review
Polyendocrine metabolic ovarian syndrome (PMOS), formerly known as polycystic ovary syndrome (PCOS), is a complex endocrine and metabolic disorder associated with insulin resistance, chronic low-grade inflammation, reproductive dysfunction, and reduced quality of life. Although physical activity is a cornerstone of PMOS management, the relative effectiveness of different exercise modalities remains unclear. To compare the effects of aerobic exercise, resistance training, and high-intensity interval training (HIIT) on metabolic, reproductive, inflammatory, and psychological outcomes in women with PMOS. A narrative literature review was conducted using PubMed and Google Scholar. Original studies, randomized controlled trials, observational studies, reviews, and clinical guidelines evaluating exercise interventions in women with PMOS/PCOS were included. Due to heterogeneity in study designs and outcomes, findings were synthesized qualitatively. Aerobic exercise, resistance training, and HIIT all demonstrated beneficial effects in women with PMOS. Aerobic exercise improved body composition, insulin sensitivity, cardiovascular fitness, and psychological well-being. Resistance training was particularly effective in increasing lean body mass and improving metabolic health, whereas HIIT provided a time-efficient strategy with favorable effects on insulin sensitivity and cardiorespiratory fitness. Combined exercise interventions appeared to offer the broadest benefits by targeting multiple pathophysiological mechanisms. Exercise is a key component of PMOS management. Although no single modality appears universally superior, resistance training and HIIT may provide additional metabolic benefits beyond aerobic exercise. Exercise programs should be individualized according to patient characteristics and treatment goals. Further high-quality randomized controlled trials are needed to establish evidence-based recommendations for optimal exercise strategies in women with PMOS.
- 8 August 2026
- Published by Uniwersytet Mikolaja Kopernika/Nicolaus Copernicus University in Quality in Sport
- Vol. 67, 74323
Open AccessComparison of different exercise modalities in women with polyendocrine metabolic ovarian syndrome: a narrative review
Polyendocrine metabolic ovarian syndrome (PMOS), formerly known as polycystic ovary syndrome (PCOS), is a complex endocrine and metabolic disorder associated with insulin resistance, chronic low-grade inflammation, reproductive dysfunction, and reduced quality of life. Although physical activity is a cornerstone of PMOS management, the relative effectiveness of different exercise modalities remains unclear. To compare the effects of aerobic exercise, resistance training, and high-intensity interval training (HIIT) on metabolic, reproductive, inflammatory, and psychological outcomes in women with PMOS. A narrative literature review was conducted using PubMed and Google Scholar. Original studies, randomized controlled trials, observational studies, reviews, and clinical guidelines evaluating exercise interventions in women with PMOS/PCOS were included. Due to heterogeneity in study designs and outcomes, findings were synthesized qualitatively. Aerobic exercise, resistance training, and HIIT all demonstrated beneficial effects in women with PMOS. Aerobic exercise improved body composition, insulin sensitivity, cardiovascular fitness, and psychological well-being. Resistance training was particularly effective in increasing lean body mass and improving metabolic health, whereas HIIT provided a time-efficient strategy with favorable effects on insulin sensitivity and cardiorespiratory fitness. Combined exercise interventions appeared to offer the broadest benefits by targeting multiple pathophysiological mechanisms. Exercise is a key component of PMOS management. Although no single modality appears universally superior, resistance training and HIIT may provide additional metabolic benefits beyond aerobic exercise. Exercise programs should be individualized according to patient characteristics and treatment goals. Further high-quality randomized controlled trials are needed to establish evidence-based recommendations for optimal exercise strategies in women with PMOS.
- Open Access
- 2 July 2026
- Published by RS Global Sp. z O.O. in International Journal of Innovative Technologies in Social Science
- Vol. 1 (3(51))
FRAILTY SYNDROME IN CLINICAL NEUROLOGY: A COMPREHENSIVE REVIEW OF NERVOUS SYSTEM PATHOPHYSIOLOGY, PROGNOSIS IN SELECTED CONDITIONS, AND SOCIO-TECHNOLOGICAL PERSPECTIVES
Background: Neurological conditions are now the leading cause of disability worldwide. Frailty syndrome, defined as a multisystemic state of physiological impairment, often predicts clinical outcomes more accurately than chronological age. Objective: This review examines the molecular pathophysiology of neuro-frailty, its prognostic significance in acute ischemic stroke, multiple sclerosis (MS), and Parkinson’s disease (PD), as well as the integration of emerging diagnostic technologies. Methodology: A comprehensive review of English-language articles published from 2001 to 2026 in PubMed, Scopus, and Cochrane was conducted. Grey literature and animal studies were excluded from the analysis. The synthesis focused on meta-analyses and human-based research connecting artificial intelligence diagnostics, fluid biomarkers, and clinical neurology. Results: Neuro-frailty is associated with the phenomenon of inflammaging, the secretory ageing-associating phenotype (SASP), and progressive mitochondrial dysfunction. The presence of pre-existing frailty also elevates the risk of unfavorable functional recovery (mRS > 2) in acute phase of ischaemic stroke by 3.11 times. In MS, ongoing neurodegeneration accelerates biological ageing, often resulting in premature frailty. The sarcopenia-frailty axis in Parkinson’s disease affects over 35% of patients and significantly increases the risk of recurrent falls. Modern diagnostic methods now enable objective and precise quantification of this impairment. Conclusions: Frailty is a dynamic clinical condition that is possible to reverse. The transition from age-based metrics to AI-powered biological screening enables a personalized approach to care by clinicians. These targeted strategies are essential for maintaining neurological functions and reducing socio-economic consequences of ageing.
- 2 July 2026
- Published by RS Global Sp. z O.O. in International Journal of Innovative Technologies in Social Science
- Vol. 1 (3(51))
Open AccessFRAILTY SYNDROME IN CLINICAL NEUROLOGY: A COMPREHENSIVE REVIEW OF NERVOUS SYSTEM PATHOPHYSIOLOGY, PROGNOSIS IN SELECTED CONDITIONS, AND SOCIO-TECHNOLOGICAL PERSPECTIVES
Background: Neurological conditions are now the leading cause of disability worldwide. Frailty syndrome, defined as a multisystemic state of physiological impairment, often predicts clinical outcomes more accurately than chronological age. Objective: This review examines the molecular pathophysiology of neuro-frailty, its prognostic significance in acute ischemic stroke, multiple sclerosis (MS), and Parkinson’s disease (PD), as well as the integration of emerging diagnostic technologies. Methodology: A comprehensive review of English-language articles published from 2001 to 2026 in PubMed, Scopus, and Cochrane was conducted. Grey literature and animal studies were excluded from the analysis. The synthesis focused on meta-analyses and human-based research connecting artificial intelligence diagnostics, fluid biomarkers, and clinical neurology. Results: Neuro-frailty is associated with the phenomenon of inflammaging, the secretory ageing-associating phenotype (SASP), and progressive mitochondrial dysfunction. The presence of pre-existing frailty also elevates the risk of unfavorable functional recovery (mRS > 2) in acute phase of ischaemic stroke by 3.11 times. In MS, ongoing neurodegeneration accelerates biological ageing, often resulting in premature frailty. The sarcopenia-frailty axis in Parkinson’s disease affects over 35% of patients and significantly increases the risk of recurrent falls. Modern diagnostic methods now enable objective and precise quantification of this impairment. Conclusions: Frailty is a dynamic clinical condition that is possible to reverse. The transition from age-based metrics to AI-powered biological screening enables a personalized approach to care by clinicians. These targeted strategies are essential for maintaining neurological functions and reducing socio-economic consequences of ageing.
- Open Access
- 23 June 2026
- Published by RS Global Sp. z O.O. in International Journal of Innovative Technologies in Social Science
- Vol. 4 (2(50))
VASCULAR COGNITIVE IMPAIRMENT: RISK FACTORS, PREVENTION AND TREATMENT
Background: Vascular cognitive impairment (VCI) is a major contributor to age-associated cognitive decline, both independently and as a contributor to mixed dementia syndromes. Despite many years of research, an approved therapy has not yet been identified. Methods: We reviewed preventive and therapeutic strategies tested in VCI and meta-analyzed efficacy data for eligible interventions to assess whether previously tested treatments warranted reconsideration. Results: VCI clinical trials exhibited substantial heterogeneity. Few interventions were reproducibly tested in adequately sized and designed studies. Nonetheless, some interventions showed modest effects on global cognition and functional outcomes. Conclusion: Early and effective management of cerebrovascular risk factors, particularly beginning in midlife, plays a crucial role in lowering the likelihood of developing neurodegenerative conditions such a vascular cognitive impairment and other related dementias. Ginkgo biloba extracts and acetylcholinesterase inhibitors have shown the greatest cognitive and functional benefits, though their clinical significance remains uncertain, and certainty of evidence is overall low.
- 23 June 2026
- Published by RS Global Sp. z O.O. in International Journal of Innovative Technologies in Social Science
- Vol. 4 (2(50))
Open AccessVASCULAR COGNITIVE IMPAIRMENT: RISK FACTORS, PREVENTION AND TREATMENT
Background: Vascular cognitive impairment (VCI) is a major contributor to age-associated cognitive decline, both independently and as a contributor to mixed dementia syndromes. Despite many years of research, an approved therapy has not yet been identified. Methods: We reviewed preventive and therapeutic strategies tested in VCI and meta-analyzed efficacy data for eligible interventions to assess whether previously tested treatments warranted reconsideration. Results: VCI clinical trials exhibited substantial heterogeneity. Few interventions were reproducibly tested in adequately sized and designed studies. Nonetheless, some interventions showed modest effects on global cognition and functional outcomes. Conclusion: Early and effective management of cerebrovascular risk factors, particularly beginning in midlife, plays a crucial role in lowering the likelihood of developing neurodegenerative conditions such a vascular cognitive impairment and other related dementias. Ginkgo biloba extracts and acetylcholinesterase inhibitors have shown the greatest cognitive and functional benefits, though their clinical significance remains uncertain, and certainty of evidence is overall low.
- Open Access
- 15 May 2026
- Published by RS Global Sp. z O.O. in International Journal of Innovative Technologies in Social Science
- Vol. 2 (2(50))
TRASTUZUMAB - REVIEW OF USE AND EFFECTIVENESS IN THE TREATMENT OF HER2-POSITIVE NEOPLASM
Treating cancers is a challenge that many scientists from around the world face every day. Thanks to the scientific advances, cancers are now divided not only by the organ they affect, but also into subtypes such as histological and molecular. Small molecules present on cancer cells have become the target of molecular drugs, making cancer treatment even more personalized for specific type. One of them is the use of trastuzumab - a targeted monoclonal antibody used in the treatment of cancers with overexpression of the HER2 protein on cell membrane. Trastuzumab inhibits the growth of cancer cells by blocking HER2 receptors. This mechanism is used in the treatment of HER2-positive breast and stomach cancer. In clinical trials, trastuzumab has been shown to have significantly higher rates of disease-free survival, absolute survival rate, median overall survival, progression-free survival and the duration of response than similar therapies without it. This makes it promising and useful in anticancer therapy in some neoplasm types. In addition, the safety profile has been checked and assessed in many respects, taking into account the side effects that this drug causes.
- 15 May 2026
- Published by RS Global Sp. z O.O. in International Journal of Innovative Technologies in Social Science
- Vol. 2 (2(50))
Open AccessTRASTUZUMAB - REVIEW OF USE AND EFFECTIVENESS IN THE TREATMENT OF HER2-POSITIVE NEOPLASM
Treating cancers is a challenge that many scientists from around the world face every day. Thanks to the scientific advances, cancers are now divided not only by the organ they affect, but also into subtypes such as histological and molecular. Small molecules present on cancer cells have become the target of molecular drugs, making cancer treatment even more personalized for specific type. One of them is the use of trastuzumab - a targeted monoclonal antibody used in the treatment of cancers with overexpression of the HER2 protein on cell membrane. Trastuzumab inhibits the growth of cancer cells by blocking HER2 receptors. This mechanism is used in the treatment of HER2-positive breast and stomach cancer. In clinical trials, trastuzumab has been shown to have significantly higher rates of disease-free survival, absolute survival rate, median overall survival, progression-free survival and the duration of response than similar therapies without it. This makes it promising and useful in anticancer therapy in some neoplasm types. In addition, the safety profile has been checked and assessed in many respects, taking into account the side effects that this drug causes.